Best of ASCO - 2014 Annual Meeting

 

Welcome

Other Novel Agents

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours.

Udai Banerji

TPS2610

A phase 1/2 study of relacorilant + nab-paclitaxel (nab-pac) in patients (pts) with solid tumors: The dose-finding phase.

Pamela N. Munster

2554

A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.

John Sarantopoulos

TPS2612

A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).

Michael S. Gordon

2547

A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results.

Baukelien Van Triest

2518

A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers.

Kwang-Yu Chang

2556

A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer.

Jaydira Del Rivero

TPS2608

Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).

Miguel Quintela-Fandino

2552

Absence of indicators of hypercoagulability and antiphospholipid syndrome in bxq-350 first in human study.

Charles A Cruze

e14533

Allometric scaling of preclinical pharmacokinetic and toxicokinetic parameters to predict clinical pharmacokinetics of BXQ-350 saposin C protein-phosphatidylserine nanovesicles.

Charles A Cruze

e14537

Cardiovascular effects of rehabilitation in hormone-dependent breast cancer patient with the postcastration syndrome.

Oleg Ivanovich Kit

e14530

Characterization of KEAP1-NRF2 genomic alterations across diverse tumor types: Co-occurring alterations, survival outcomes, and implications for targeting cancer metabolism.

Shiraj Sen

2558

Comparison of SUV and RECIST responses in cancers treated with SM-88.

Dacian V. Bonta

e14528

Development of the triple-mutant oncolytic adenovirus for treatment of metastatic cancer by means of intravascular virus administration.

Dmitry Shayakhmetov

e14546

Efficacy and tolerability of nanoparticle docetaxel lipid suspension.

Aditya Murali

e14542

First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.

Analia Azaro

2520

First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.

Toshio Shimizu

2506

Glucocorticoid receptor PROTACs for the treatment of prostate cancer and other malignancies.

James Thomas Link

e14545

Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials.

Robert J Holt

2559

Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.

Judy Sing-Zan Wang

2560

NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.

Anita Ahmed Turk

2548

Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial.

Susen Burock

e14536

Oncolytic and preventive effect of a new strain of rotavirus (family Reoviridae) on Guerin carcinoma growth in the experiment.

Sergey A. Kolpakov

e14534

Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.

Francine M. Foss

2511

Pharmacodynamics of first-in-class p97 inhibitors that disrupt protein homeostasis in cancer.

Apurva K. Srivastava

e14539

Phase 1 study of ANDES-1537: A novel antisense oligonucleotide against non-coding mitochondrial DNA in advanced solid tumors.

Mallika Sachdev Dhawan

2557

Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies.

Yada Kanjanapan

TPS2609

Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.

Jennifer Rachel Eads

2562

Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.

Jennifer Robinson Diamond

2507

Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.

Andrea Wang-Gillam

2561

Phase I study of muscadine grape extract in advanced malignancy.

Rhonda L. Bitting

e14548

Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation.

Sarina Anne Piha-Paul

TPS2611

Phase I trial of lurbinectedin (PM1183) in Japanese patients with advanced tumors: Results of the dose escalation part.

Shunji Takahashi

2551

Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.

Geraldine Helen O'Sullivan Coyne

2549

Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptor–positive solid tumors including desmoid and gynecologic tumors.

Naoko Takebe

2516

Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.

Amita Patnaik

2550

Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period–The IMPACT study.

Apostolia Maria Tsimberidou

LBA2553

Preclinical development of sunitinib and nivolumab in osteosarcoma and synovial sarcoma: In vitro functional studies.

Emanuela Palmerini

e14543

Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

Debashis Sarker

2509

Protease-activatable cell-penetrating peptides as prodrugs for delivery of cytotoxins into tumors.

Andrew J Gale

e14538

Real world results of liquid biopsy in stage 3/4 solid tumors and potential ''clinical actionability."

Rebecca Christian Arend

2555

Safety and metabolic effects of cyclic fasting mimicking diet (FMD) in cancer patients.

Filippo G. De Braud

e14549

SM-88 efficacy across multiple high-risk factors.

Xinhua Zhu

e14535

Targeted MCL-1 inhibition to induce cell death and synergize with conventional chemotherapeutic agents in diffuse large B-cell lymphoma (DLBCL) pre-clinical models.

Robert Zachary Ferdman

e14540

Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.

Jaime R. Merchan

TPS2613